| Literature DB >> 32978497 |
Kamal El-Din M Mokbel1, Ibrahim R Baiuomy2, Abd El-Hamid A Sabry1, Mona M Mohammed3, Marwa A El-Dardiry4.
Abstract
Schistosomiasis is a serious parasitic infection affecting millions worldwide. This study aimed to explore the anti-schistosomal activity of curcumin and curcumin loaded gold-nanoparticles (Cur-GNPs) with or without praziquantel (PZQ). We used six groups of the C57BL/6 mice in which five groups were infected with Schistosoma Mansoni (S. mansoni) cercariae and exhibited, separately, to different treatment regimens of curcumin, curcumin loaded nanoparticle, and PZQ, in addition to one untreated group which acts as a control. Mice were sacrificed at the 8th week where both worms and eggs were counted in the hepatic and porto-mesenteric vessels in the liver and intestine, respectively, in addition to a histopathological examination of the liver granuloma. Curcumin caused a significant reduction in the worms and egg count (45.45%) at the 3rd week. A significant schistosomicidal effect of PZQ was found in all groups. Cur-GNPs combined with PZQ 97.4% reduction of worm burden in the 3rd week and the highest reduction in the intestinal and hepatic egg content, as well, besides 70.1% reduction of the granuloma size. The results suggested the curcumin in combination with PZQ as a strong schistosomicidal regimen against S. mansoni as it alters the hematological, biochemical, and immunological changes induced.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32978497 PMCID: PMC7519097 DOI: 10.1038/s41598-020-72901-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The effects of different treatments on the hematological, biochemical or immunological alterations in the S. mansonai infected groups.
| Experimental groups | Subgroups | SGOT (IU/L) | SGPT (IU/L) | TP (g/dl) | AKP | Globulin (g/dl) | TNFα | AFP | TC (mg/dl) | TG (mg/dl) | SOD | GSH |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-infected | 19.88 ± 1.73 | 18.13 ± 1.36 | 6.54 ± 0.12 | 87.25 ± 4.27 | 3.6 ± 0.05 | 15.65 ± 2.11 | 4.88 ± 1.36 | 135.13 ± 5.96 | 108.75 ± 10.69 | 22.88 ± 1.22 | 19.64 ± 0.51 | |
| 1. Infected not treated | 74.75 ± 5.42### | 64.13 ± 5.62### | 5.21 ± 0.08 | 113.88 ± 6.98## | 2.29 ± 0.24 | 188.13 ± 19.36### | 14.75 ± 1.75### | 119.88 ± 10.39 | 74.75 ± 3.69## | 8.11 ± 0.93## | 10.44 ± 0.3# | |
| 2. Curcumin | Cur-1 | 49 ± 3.74** | 40 ± 5.21** | 5.88 ± 0.15 | 99 ± 1.6 | 2.74 ± 0.16 | 66 ± 13.37*** | 13.88 ± 1.73 | 132.88 ± 26.49 | 73.13 ± 4.45 | 8.31 ± 0.57 | 11.16 ± 0.58 |
| Cur-3 | 46.75 ± 5.26** | 46.25 ± 3.62* | 5.75 ± 0.09 | 103.63 ± 2.97 | 2.76 ± 0.09 | 102.13 ± 14.17** | 14.13 ± 1.46 | 159.63 ± 7.58*** | 68.13 ± 6.58 | 9.06 ± 0.44 | 10.83 ± 0.27 | |
| 3. PZQ | 51.63 ± 2.72** | 47.13 ± 4.22* | 6.06 ± 0.09 | 104 ± 5.48 | 2.93 ± 0.1 | 104.63 ± 8.73*** | 13.38 ± 1.3 | 170.38 ± 5.24*** | 114.25 ± 24.1*** | 11.41 ± 0.64 | 11.66 ± 0.44 | |
| 4. Curcumin + PZQ | Cur-1 + PZQ | 50.38 ± 2.72** | 36.38 ± 2.2*** | 5.98 ± 0.15 | 109.13 ± 6.71 | 3.13 ± 0.09 | 95.38 ± 14.64*** | 14.75 ± 1.49 | 161.63 ± 7.84*** | 69.75 ± 5.92 | 8.65 ± 0.45 | 10.85 ± 0.37 |
| Cur-3 + PZQ | 47.13 ± 3.72** | 41.13 ± 2.42** | 6.15 ± 0.12 | 97.63 ± 3.58 | 2.8 ± 0.09 + | 101.75 ± 9.79 *** | 15.88 ± 1.96 | 149.38 ± 14.59** | 66.25 ± 1.75 | 8.69 ± 0.25 | 11.06 ± 0.48 | |
| 5. Cur-GNPs | Cur-loaded-1 | 31.88 ± 1.13*** | 29.25 ± 1.28*** | 5.49 ± 0.08 | 92.5 ± 2.07* | 2.9 ± 0.08 | 91.38 ± 5.68*** | 11.75 ± 1.04 | 152.63 ± 10.49** | 74.75 ± 3.11 | 15.96 ± 1.23** | 16.08 ± 0.28 |
| Cur-loaded-3 | 31.75 ± 1.28*** | 28.88 ± 1.55*** | 5.74 ± 0.19 | 93.38 ± 2.56 | 2.8 ± 0.08 | 34.88 ± 3.14*** | 8.5 ± 1.41 | 162.25 ± 6.39*** | 69.38 ± 2.45 | 19 ± 0.71*** | 17.28 ± 0.76* | |
| 6. Cur-GNPs + PZQ | Cur-loaded-1 + PZQ | 31.5 ± 1.2*** | 28 ± 2.07*** | 5.66 ± 1.05 | 92.75 ± 2.82* | 3.11 ± 0.08 | 37 ± 2.73*** | 9.63 ± 1.06 | 156.5 ± 10.53*** | 68.25 ± 3.5 | 14.74 ± 1.06* | 16.86 ± 0.59* |
| Cur-loaded-3 + PZQ | 31 ± 1.85*** | 30.5 ± 2.07*** | 6.31 ± 0.08 | 93.5 ± 2.51 | 3.05 ± 0.09 | 37.38 ± 4.78*** | 9.38 ± 1.19 | 130.75 ± 6.76 | 71.5 ± 4.41 | 19.54 ± 0.62*** | 17.48 ± 1.12* |
*P < 0.05, **P < 0.01, ***P < 0.001 vs. the Infected not treated mice.
#P < 0.05, ##P < 0.01, ###P < 0.001 vs. the non-infected mice.
The effects of different treatments on the worm burden in the S. mansonai infected groups.
| Experimental groups | Subgroups | Detection time (week) | Mean no. of worms | % Reduction |
|---|---|---|---|---|
| 7. Infected not treated | 8 | 33.0 | 0 | |
| Infected treated groups | ||||
| 8. Curcumin | Cur-1 | 8 | 30.5 | 7.57 |
| Cur-3 | 12 | 18.0 | 45.45 | |
| 9. PZQ | 8 | 9.0 | 72.72* | |
| 10. Curcumin + PZQ | Cur-1 + PZQ | 8 | 13.5 | 59.09 |
| Cur-3 + PZQ | 12 | 8.7 | 73.75* | |
| 11. Cur-GNPs | Cur-loaded-1 | 8 | 14.6 | 55.87 |
| Cur-loaded-3 | 12 | 19.0 | 42.42 | |
| 12. Cur-GNPs + PZQ | Cur-loaded-1 + PZQ | 8 | 4.0 | 87.87*** |
| Cur-loaded-3 + PZQ | 12 | 85.0 | 97.43*** | |
*P < 0.05, ***P < 0.001 vs. the Infected not treated.
Figure 1Anti-schistosomal effect of the different treatment regimens. Bar chart summarizes the reduction rate regarding worm burden, intestinal and hepatic load among different experimental groups. The experiments were repeated three times using at least three different samples. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the Infected not treated. The numbers 1 and 3 indicated the 1st and 3rd week of the curcumin treatment, respectively., the symbols, nano and PZQ is a pointed to Cur-GNPs and praziquantel, respectively.
The effects of different treatments on the egg load in the S. mansonai infected groups.
| Experimental groups | Subgroups | Intestinal egg load | Hepatic egg load | ||
|---|---|---|---|---|---|
| Mean ± SD | % Reduction | Mean ± SD | % Reduction | ||
| 1. Infected not treated | 38,130 ± 1100 | 0 | 46,880 ± 1132 | 0 | |
| Infected treated groups | |||||
| 2. Curcumin | Cur-1 | 35,000 ± 378 | 8.20 | 33,750 ± 791 | 28.00 |
| Cur-3 | 24,000 ± 586 | 37.05 | 30,880 ± 666 | 34.12 | |
| 3. PZQ | 2675 ± 212 | 92.98*** | 3000 ± 167 | 93.60*** | |
| 4. Curcumin + PZQ | Cur-1 + PZQ | ||||
| Cur-3 + PZQ | 21,750 ± 306 | 42.95 | 21,130 ± 223 | 54.92 | |
| 5. Cur-GNPs | Cur-loaded-1 | 8670 ± 116 | 77.30*** | 9670 ± 58 | 79.40*** |
| Cur-loaded-3 | 8670 ± 306 | 77.26*** | 7570 ± 230 | 83.85*** | |
| 6. Cur-GNPs + PZQ | Cur-loaded-1 + PZQ | ||||
| Cur-loaded-3 + PZQ | 10,000 ± 100 | 73.77*** | 25,000 ± 707 | 46.67 | |
***P < 0.001 vs. the Infected not treated.
Figure 2Sections of infected non-treated control mice. Infected non-treated control group shows cellular (black arrow), fibro-cellular (red arrows) and predominantly fibrous (Yellow arrow) granulomas with bilharzia ova. (A) Granuloma with bilharzia ova, H&E ×400. (B) Granuloma with bilharzia ova, Masson Trichrome ×400. (C) Parenchymal granuloma with bilharzia ova. H&E ×200, (D) Portal granuloma with bilharzia ova, Masson Trichrome ×200.